Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today an interim analysis of data from clinical trials of the U.S. licensed Influenza A (H1N1) 2009 Monovalent Vaccine in adults 18 years through 64 years of age and over the age of 65 years.
United Way of Southeastern Pennsylvania has launched a new regional website geared towards helping families, individuals and organizations find up-to-date information on where to go for H1N1 and seasonal influenza shots and other critical news regarding the seasonal flu epidemics expected to hit the region.
Baxter International Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) granted its “positive opinion” for CELVAPAN H1N1 pandemic vaccine using Baxter’s Vero cell technology. This positive opinion confirms the acceptability of Baxter’s regulatory submission to obtain final marketing authorization and licensure of the product.
U.S. health officials announced Thursday the first batches of the H1N1 (swine flu) vaccine the government ordered will begin arriving in designated locations across the country on Tuesday and may be administered in the first patients by the end of next week, Reuters reports (Fox, 10/1).
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Office of the Secretary, Department of Health & Human Services (HHS) has issued "HHS Secretary's Declaration for the Use of the Public Readiness and Emergency Preparedness Act for the Influenza Antiviral Peramivir."
A new study in the leading scientific journal NeuroToxicology lends further credence to parents and scientists concerned about an increasingly aggressive childhood vaccine schedule and toxic vaccine components.
Researchers at the University of Southampton have developed a new website which gives personalised advice on coping with swine flu and other cold and flu symptoms.
Thousands of bacteria lurk in college dormitories, but students are not following proper hygiene routines to help protect themselves from serious illness, according to a study released today from the Simmons College Center for Hygiene and Health in Home and Community, sponsored by an educational grant from LYSOL® brand products.
The FDA has approved the first set of vaccines aimed at preventing H1N1 infection after an approval process of less than four months. Cutting Edge Information is currently analyzing the lessons learned that may emerge for both the Food and Drug Administration (FDA) and life science firms after this crisis experience.
Drug companies are sprinting ahead in a race against the clock to deliver millions of doses of vaccine for the H1N1 influenza virus before cooler weather ushers in the 2009-2010 flu season. A two-part cover story in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine, focuses on that topic and efforts to develop antiviral drugs for flu infections.
WellCare Health Plans, Inc. (NYSE: WCG) announced it will cover the full cost of administration of the H1N1 vaccine as a preventative care benefit for Medicare Advantage, Medicare private fee-for-service (PFFS) and Medicaid plan members when it becomes available to the public.
People exposed to a H1NI strain of influenza A while in utero were significantly more likely to have cardiovascular disease later in life, reveals a new study to be published in Journal of Developmental Origins of Health and Disease on Oct. 1.
According to an article in the Wall Street Journal, the H1N1 swine flu could be severe enough to cause major staffing shortages and other workplace disruptions, the supply of vaccines to prevent the disease is taking longer to produce than originally forecast.
A majority (58%) of Americans believe that the H1N1 flu is a serious health hazard, according to a new survey released today by Silverlink Communications, Inc. This represents a marked increase as compared to May 2009, when 47% of Americans held this same perception of H1N1. While most Americans believe H1N1 is a serious health hazard, less than one-third (31%) of Americans plan on getting the H1N1 flu vaccine this year, with safety and efficacy of the vaccine cited as primary barriers for not getting the vaccine. Of particular concern, less than 27% of 18 to 24 year olds, a high risk group, plan on getting the H1N1 vaccine.
The Pennsylvania Department of Health today discussed the state's distribution plans for the new pandemic H1N1 vaccine.
According to a new Consumer Reports poll, 43 percent of American adults say they're on the fence about getting the swine flu vaccine and just 34 percent of those polled plan on getting the swine flu vaccine when it becomes available. Additionally, a mere 35 percent of parents say they'll definitely have their children vaccinated. The Centers for Disease Control and Prevention recommends that all children over the age of 6 months get the vaccine.
The first H1N1 (swine flu) vaccine shots available in the U.S. were shipped ahead of schedule after the pharmaceutical company Sanofi-Aventis finished production nearly two weeks early, the chief executive of the company said Tuesday, the New York Times reports.
BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc., today announced that BioSante stockholders have approved the merger between the two companies with BioSante as the surviving company.
House Speaker Nancy Pelosi, D-Calif., on Tuesday commended Tanazanian President Jakaya Kikwete on the country's utilization of U.S. aid money and vowed her support for the country's future development projects, during a meeting in Washington, D.C., the Zimbabwean reports. "Pelosi hailed President Kikwete and his government for the commitment demonstrated by the campaigns against HIV/AIDS, malaria and TB and implementation of MCC programmes," the newspaper writes (Kulekana, 9/30).
BioCryst Pharmaceuticals, Inc. today announced that it has delivered a written response to the request for proposal (RFP) announced on September 21, 2009 from the U.S. Department of Health & Human Services (HHS) for the supply of intravenous (i.v) peramivir for the treatment of critically ill influenza patients under Emergency Use Authorization (EUA). BioCryst management intends to provide an update once the RFP process has reached a conclusion.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.